Recap: Arcus Biosciences Q4 Earnings
Portfolio Pulse from Benzinga Insights
Arcus Biosciences (NYSE:RCUS) reported Q4 earnings with an EPS of $-1.08, missing estimates by 5.88% and a revenue decrease of $3M from the previous year. This follows a pattern of mixed past earnings performance, with the company previously beating EPS estimates in Q3 2023 but experiencing a share price drop the next day.
February 21, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Arcus Biosciences reported a Q4 EPS of $-1.08, missing estimates by 5.88%, and a year-over-year revenue decrease of $3M.
Missing earnings estimates and reporting a revenue decrease are typically seen as negative indicators for a company's financial health, likely leading to a negative short-term impact on the stock price. Historical data shows a share price drop following the last earnings beat, suggesting sensitivity to earnings reports.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100